CN109507323A - A kind of kit with LBP content in mass spectrograph detection human blood - Google Patents
A kind of kit with LBP content in mass spectrograph detection human blood Download PDFInfo
- Publication number
- CN109507323A CN109507323A CN201811496455.1A CN201811496455A CN109507323A CN 109507323 A CN109507323 A CN 109507323A CN 201811496455 A CN201811496455 A CN 201811496455A CN 109507323 A CN109507323 A CN 109507323A
- Authority
- CN
- China
- Prior art keywords
- lbp
- sample
- kit
- mass spectrograph
- human blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention belongs to kit technical fields, a kind of kit with LBP content in mass spectrograph detection human blood is disclosed, the kit with LBP content in mass spectrograph detection human blood includes: 30 times of concentrated cleaning solutions, enzyme marking reagent, enzyme mark coating plate, sample diluting liquid, color developing agent A, color developing agent B, terminate liquid, standard items, standard dilutions, mass spectrograph；The present invention by using high specific primer and proper method combination, it can be realized quick, easy, accurate, efficient, practical, economic detection LBP gene label SNP genotype, it can be used for generation, developing risk of the LBP gene in the association study of disease genetic susceptibility, conducive to LBP gene label SNP detection predictive disease；Meanwhile the dilution testing result provided is accurately reliable, dispersion effect is good, can save steadily in the long term, and can be universally used in the serum or plasma sample dilution of different clinical immunization checkup items, is of great significance for clinical medicine diagnosis.
Description
Technical field
The invention belongs to kit technical field more particularly to a kind of LBP contents in mass spectrograph detection human blood
Kit.
Background technique
Lipopolysaccharides (1ipopolysaccharide, LPS) is also known as endotoxin, be gram-negative bacteria outer membrane it is main at
Point.LPS and acute phase protein lipopolysaccharide binding protein (lipopolysaccharidebindingprotein, LBP) are combined, can
Cause inflammatory reaction out of control and the decline of immune defense barrier function, causes systemic inflammatory response syndrome, septic shock, acute
Injury of lungs even multiple organ dysfunction syndrome.Lipopolysaccharide binding protein (lipopolysaccharidebindingprote
In, LBP) it be a kind of molecular weight is 60kDa, the glycoprotein of 456 amino acid composition, in the form of single chain polypeptide in liver cell
Synthesis, it belongs to I type acute phase reactive protein, is present in the serum of humans and animals.LBP both can be by bacteria lipopolysaccharide
(lipopolysaccharide, LPS) polymer is converted to single aggressiveness, accelerates LPS in conjunction with its receptor CD14, greatly enlarged
The proinflammatory effect of LPS；It can also accelerate LPS in conjunction with the removing acceptor on target cell membrane, remove LPS by target cell；It can also urge
Change LPS in conjunction with lipoprotein, the latter can neutralize the biological activity of LPS, the removing of LPS in acceleration bodies.However, existing use mass spectrum
The kit of LBP content cannot detect LBP gene label single nucleotide polymorphism site, function list in instrument detection human blood
One；Meanwhile existing serum or plasma sample viscosity are all higher, using merely using people's negative serum or blood plasma, calf serum
It is diluted, examined time restriction, it tends to be difficult to which dilution is uniformly mixed, and causing testing result to be easy, there are certain deviations.
In conclusion problem of the existing technology is: the existing reagent with LBP content in mass spectrograph detection human blood
Box cannot detect LBP gene label single nucleotide polymorphism site, have a single function；Meanwhile existing serum or plasma sample are sticky
Degree is all higher, and using being diluted using people's negative serum or blood plasma, calf serum merely, examined time restriction is often difficult
It is uniformly mixed with diluting, causing testing result to be easy, there are certain deviations.
Summary of the invention
In view of the problems of the existing technology, the present invention provides a kind of with LBP content in mass spectrograph detection human blood
Kit.
The invention is realized in this way a kind of kit with LBP content in mass spectrograph detection human blood includes:
30 times of concentrated cleaning solutions, enzyme marking reagent, enzyme mark coating plate, sample diluting liquid, color developing agent A, color developing agent B, terminate liquid,
Standard items, standard dilutions, mass spectrograph；
Terminate liquid is HCl and H2SO4；
Color developing agent A is by PBS buffer solution, citric acid, ED-TA disodium salt, ProcLin-300, hydrogen peroxide (mistake
Hydrogen oxide volatility is too high, is easily lost, we are just being replaced with urea peroxide now, and effect is well) composition；
Color developing agent B is by PBS buffer solution, citric acid, ED-TA disodium salt, ProcLin-300, sodium thiosulfate
Deng.
A kind of kit test method with LBP content in mass spectrograph detection human blood is as follows:
Step 1, standard items are added standard dilutions and are diluted；
Step 2, sample-adding；
Set respectively blank well (sample and enzyme marking reagent is not added in blank control wells, remaining each step operation is identical), gauge orifice, to
Test sample sample wells.Standard items are accurately loaded 50 μ l on enzyme mark coating plate, first add 40 μ l of sample diluting liquid in sample to be tested hole, then
Again plus 10 μ l of sample to be tested (the final dilution of sample be 5 times).Sample is added on ELISA Plate hole bottom by sample-adding, does not touch hole as far as possible
Wall shakes gently mixing；
Step 3 is incubated 30 minutes with 37 DEG C of postposition of sealing plate film sealing plate；
Step 4, will be spare after 30 times of concentrated cleaning solutions, 30 times of distilled water dilutions；
Step 5 carefully takes sealing plate film off, discards liquid, and cleaning solution is filled it up in drying, every hole, discards after standing 30 seconds, such as
This is repeated 5 times, and pats dry；
Step 6, every hole are added 50 μ l of enzyme marking reagent, except blank well；Repeat step 3 and step 5 operation；
Color developing agent A50 μ l is first added in step 7, every hole, adds color developing agent B50 μ l, and gently concussion mixes, and 37 DEG C are protected from light
Colour developing 15 minutes；
Step 8, every hole add 50 μ l of terminate liquid, terminate reaction (blue is vertical at this time turns yellow)；
Step 9 detects aforesaid liquid using efficient liquid phase tandem mass spectrometer, obtains LBP chromatogram in blood,
Calculate LBP content data in human blood.
Further, the detection method in the LBP gene label single nucleotide polymorphism site is as follows:
1) design of specific primer
According to the LBP gene label single nucleotide polymorphism site being proved, designs specificity amplification primer and sequencing is drawn
Object, wherein one in the specificity amplification primer with biotin labeling；
2) PCR amplification
Using the DNA of sample to be measured as template, PCR reaction is carried out with the specificity amplification primer described in step 1), obtains PCR expansion
Increase object；
3) pyrosequencing
It uses alkaline denaturation to be separated into it PCR amplification object obtained by step 2) single-stranded, takes the list wherein by biotin labeling
Chain pcr amplification product carries out hybridization reaction after purification, with sequencing primer described in step 1), and it is described to be measured to judge to analyze result
Whether the target monokaryon sweet acid of sample has polymorphism.
Further, the standard dilutions include: buffer solution, albumin, and the content of the albumin is 10~
100g/L, alkali metal chloride, optional emulsifier；And the pH value of the dilution is 6.0~8.0.
Further, the albumin is selected from: haemocyanin, lactalbumin, ovalbumin.
Further, the buffer solution is selected from: phosphate buffer solution (PB), phosphate buffer solution (PBS), trihydroxy methyl
Aminomethane-hydrochloric acid buffer solution (Tris-HCl) or combinations thereof.
Further, the dilution further includes one or more components selected from the group below:
(a) chelate of metal ion；
(b) alkali metal sulfates；
(c) preservative.
Further, the dilution has one or more characteristics below:
(a) the conductivity ρ of the dilution at room temperature is 0.55 × 104~0.75 × 104μS/cm；
(b) it is 250~380mOsm/Kg that the dilution, which is the osmotic pressure that sample to be tested provides,；
(c) pH of the dilution is 7.2~7.8.
Advantages of the present invention and good effect are as follows: the present invention by using high specific primer and proper method combination,
It can be realized quick, easy, accurate, efficient, practical, economic detection LBP gene label SNP genotype, can be used for LBP gene
It in the association study of disease genetic susceptibility, can satisfy the needs of clinical examination real work, be conducive to LBP gene label SNP
Detect generation, the developing risk of predictive disease.It compared with prior art, can quickly, accurately using pyrosequencing techniques
Ground carries out the analysis of short dna sequence, convenient for building normalizing operation process, has many advantages, such as high accurate, high-throughput, low cost；PCR
Amplimer is high-efficient, and product can directly carry out pyrosequencing, easy to operate without carrying out the secondary treatments such as product purification,
Amount of samples is few；Meanwhile the dilution testing result provided is accurately reliable, and dispersion effect is good, it can save steadily in the long term, and
The serum or plasma sample dilution that can be universally used in different clinical immunization checkup items have clinical medicine diagnosis important
Meaning.
Detailed description of the invention
Fig. 1 is the reagent cartridge configuration block diagram provided in an embodiment of the present invention with LBP content in mass spectrograph detection human blood.
Fig. 2 is the kit test method provided in an embodiment of the present invention with LBP content in mass spectrograph detection human blood
Flow chart.
Specific embodiment
In order to further understand the content, features and effects of the present invention, the following examples are hereby given, and cooperate attached drawing
Detailed description are as follows.
Structure of the invention is explained in detail with reference to the accompanying drawing.
As shown in Figure 1, the kit provided by the invention with LBP content in mass spectrograph detection human blood includes: 30 times
Concentrated cleaning solution, enzyme marking reagent, enzyme mark are coated with plate, sample diluting liquid, color developing agent A, color developing agent B, terminate liquid, standard items, standard
Product dilution, mass spectrograph；
Terminate liquid is HCl and H2SO4；
Color developing agent A is by PBS buffer solution, citric acid, ED-TA disodium salt, ProcLin-300, hydrogen peroxide (mistake
Hydrogen oxide volatility is too high, is easily lost, we are just being replaced with urea peroxide now, and effect is well) composition；
Color developing agent B is by PBS buffer solution, citric acid, ED-TA disodium salt, ProcLin-300, sodium thiosulfate
Deng.
As shown in Fig. 2, a kind of kit test method with LBP content in mass spectrograph detection human blood is as follows:
Step S101, standard items are added standard dilutions and are diluted；
Step S102, sample-adding；
Set respectively blank well (sample and enzyme marking reagent is not added in blank control wells, remaining each step operation is identical), gauge orifice, to
Test sample sample wells.Standard items are accurately loaded 50 μ l on enzyme mark coating plate, first add 40 μ l of sample diluting liquid in sample to be tested hole, then
Again plus 10 μ l of sample to be tested (the final dilution of sample be 5 times).Sample is added on ELISA Plate hole bottom by sample-adding, does not touch hole as far as possible
Wall shakes gently mixing；
Step S103 is incubated 30 minutes with 37 DEG C of postposition of sealing plate film sealing plate；
Step S104, will be spare after 30 times of concentrated cleaning solutions, 30 times of distilled water dilutions；
Step S105 carefully takes sealing plate film off, discards liquid, and cleaning solution is filled it up in drying, every hole, discards after standing 30 seconds,
It is so repeated 5 times, pats dry；
Step S106, every hole are added 50 μ l of enzyme marking reagent, except blank well；Repeat step 3 and step 5 operation；
Color developing agent A50 μ l is first added in step S107, every hole, adds color developing agent B50 μ l, and gently concussion mixes, and 37 DEG C are kept away
Light develops the color 15 minutes；
Step S108, every hole add 50 μ l of terminate liquid, terminate reaction (blue is vertical at this time turns yellow)；
Step S109 detects aforesaid liquid using efficient liquid phase tandem mass spectrometer, obtains LBP chromatography in blood
Figure calculates LBP content data in human blood.
The detection method in LBP gene label single nucleotide polymorphism site provided by the invention is as follows:
1) design of specific primer
According to the LBP gene label single nucleotide polymorphism site being proved, designs specificity amplification primer and sequencing is drawn
Object, wherein one in the specificity amplification primer with biotin labeling；
2) PCR amplification
Using the DNA of sample to be measured as template, PCR reaction is carried out with the specificity amplification primer described in step 1), obtains PCR expansion
Increase object；
3) pyrosequencing
It uses alkaline denaturation to be separated into it PCR amplification object obtained by step 2) single-stranded, takes the list wherein by biotin labeling
Chain pcr amplification product carries out hybridization reaction after purification, with sequencing primer described in step 1), and it is described to be measured to judge to analyze result
Whether the target monokaryon sweet acid of sample has polymorphism.
Standard dilutions provided by the invention include: buffer solution, albumin, and the content of the albumin is 10~
100g/L, alkali metal chloride, optional emulsifier；And the pH value of the dilution is 6.0~8.0.
Albumin provided by the invention is selected from: haemocyanin, lactalbumin, ovalbumin.
Buffer solution provided by the invention is selected from: phosphate buffer solution (PB), phosphate buffer solution (PBS), three hydroxyl first
Base aminomethane-hydrochloric acid buffer solution (Tris-HCl) or combinations thereof.
Dilution provided by the invention further includes one or more components selected from the group below:
(a) chelate of metal ion；
(b) alkali metal sulfates；
(c) preservative.
Dilution provided by the invention has one or more characteristics below:
(a) the conductivity ρ of the dilution at room temperature is 0.55 × 104~0.75 × 104μS/cm；
(b) it is 250~380mOsm/Kg that the dilution, which is the osmotic pressure that sample to be tested provides,；
(c) pH of the dilution is 7.2~7.8.
The above is only the preferred embodiments of the present invention, and is not intended to limit the present invention in any form,
Any simple modification made to the above embodiment according to the technical essence of the invention, equivalent variations and modification, belong to
In the range of technical solution of the present invention.
Claims (8)
1. a kind of kit with LBP content in mass spectrograph detection human blood, which is characterized in that described to detect people with mass spectrograph
The kit of LBP content includes: in class blood
30 times of concentrated cleaning solutions, enzyme marking reagent, enzyme mark are coated with plate, sample diluting liquid, color developing agent A, color developing agent B, terminate liquid, standard
Product, standard dilutions, mass spectrograph；
Terminate liquid is HCl and H2SO4；
Color developing agent A is by PBS buffer solution, citric acid, ED-TA disodium salt, ProcLin-300, hydrogen peroxide (peroxidating
Hydrogen volatility is too high, is easily lost, we are just being replaced with urea peroxide now, and effect is well) composition；
Color developing agent B is by PBS buffer solution, citric acid, ED-TA disodium salt, ProcLin-300, sodium thiosulfate etc..
2. as described in claim 1 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that the use
The kit test method that mass spectrograph detects LBP content in human blood is as follows:
Step 1, standard items are added standard dilutions and are diluted；
Step 2, sample-adding；
Blank well (sample and enzyme marking reagent is not added in blank control wells, remaining each step operation is identical), gauge orifice are set respectively, to test sample
Sample wells.Standard items are accurately loaded 50 μ l on enzyme mark coating plate, first add 40 μ l of sample diluting liquid in sample to be tested hole, then add again
10 μ l of sample to be tested (the final dilution of sample is 5 times).Sample is added on ELISA Plate hole bottom by sample-adding, does not touch hole wall as far as possible,
Shake gently mixing；
Step 3 is incubated 30 minutes with 37 DEG C of postposition of sealing plate film sealing plate；
Step 4, will be spare after 30 times of concentrated cleaning solutions, 30 times of distilled water dilutions；
Step 5 carefully takes sealing plate film off, discards liquid, and cleaning solution is filled it up in drying, every hole, discards after standing 30 seconds, so weight
It is 5 times multiple, it pats dry；
Step 6, every hole are added 50 μ l of enzyme marking reagent, except blank well；Repeat step 3 and step 5 operation；
Color developing agent A50 μ l is first added in step 7, every hole, adds color developing agent B50 μ l, and gently concussion mixes, and 37 DEG C are protected from light colour developing
15 minutes；
Step 8, every hole add 50 μ l of terminate liquid, terminate reaction (blue is vertical at this time turns yellow)；
Step 9 detects aforesaid liquid using efficient liquid phase tandem mass spectrometer, obtains LBP chromatogram in blood, calculates
LBP content data in human blood.
3. as described in claim 1 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that the LBP
The detection method in gene label single nucleotide polymorphism site is as follows:
1) design of specific primer
According to the LBP gene label single nucleotide polymorphism site being proved, specificity amplification primer and sequencing primer are designed,
In, one in the specificity amplification primer with biotin labeling；
2) PCR amplification
Using the DNA of sample to be measured as template, PCR reaction is carried out with the specificity amplification primer described in step 1), obtains PCR amplification
Object；
3) pyrosequencing
It uses alkaline denaturation to be separated into it PCR amplification object obtained by step 2) single-stranded, takes the single-stranded PCR wherein by biotin labeling
Amplified production carries out hybridization reaction after purification, with sequencing primer described in step 1), and analyzes result to judge the sample to be measured
Target monokaryon sweet acid whether have polymorphism.
4. as described in claim 1 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that the mark
Quasi- product dilution includes: buffer solution, albumin, and the content of the albumin is 10~100g/L, alkali metal chloride, optionally
Emulsifier；And the pH value of the dilution is 6.0~8.0.
5. as claimed in claim 4 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that described white
Albumen is selected from: haemocyanin, lactalbumin, ovalbumin.
6. as claimed in claim 4 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that described slow
It rushes solution to be selected from: phosphate buffer solution (PB), phosphate buffer solution (PBS), trishydroxymethylaminomethane-hydrochloric acid buffer solution
(Tris-HCl) or combinations thereof.
7. as claimed in claim 4 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that described dilute
Releasing liquid further includes one or more components selected from the group below:
(a) chelate of metal ion；
(b) alkali metal sulfates；
(c) preservative.
8. as claimed in claim 4 with the kit of LBP content in mass spectrograph detection human blood, which is characterized in that described dilute
Liquid is released with one or more characteristics below:
(a) the conductivity ρ of the dilution at room temperature is 0.55 × 104~0.75 × 104μS/cm；
(b) it is 250~380mOsm/Kg that the dilution, which is the osmotic pressure that sample to be tested provides,；
(c) pH of the dilution is 7.2~7.8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811496455.1A CN109507323A (en) | 2018-12-07 | 2018-12-07 | A kind of kit with LBP content in mass spectrograph detection human blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811496455.1A CN109507323A (en) | 2018-12-07 | 2018-12-07 | A kind of kit with LBP content in mass spectrograph detection human blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109507323A true CN109507323A (en) | 2019-03-22 |
Family
ID=65753133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811496455.1A Pending CN109507323A (en) | 2018-12-07 | 2018-12-07 | A kind of kit with LBP content in mass spectrograph detection human blood |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109507323A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113008880A (en) * | 2021-02-26 | 2021-06-22 | 必为(上海)医疗器械有限公司 | Medical instrument residual blood detection kit and using method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1139485A (en) * | 1994-01-24 | 1997-01-01 | 爱克斯欧玛公司 | Method for quantifying LBP in body fluids |
| CN103487313A (en) * | 2013-10-21 | 2014-01-01 | 上海蓝怡科技有限公司 | Serum or plasma sample diluent and application thereof |
| CN103602753A (en) * | 2013-12-09 | 2014-02-26 | 中国人民解放军第三军医大学第三附属医院 | Method and kit for detecting single nucleotide polymorphism site of LBP (Lipopolysaccharide-Binding Protein) genetic label |
-
2018
- 2018-12-07 CN CN201811496455.1A patent/CN109507323A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1139485A (en) * | 1994-01-24 | 1997-01-01 | 爱克斯欧玛公司 | Method for quantifying LBP in body fluids |
| CN103487313A (en) * | 2013-10-21 | 2014-01-01 | 上海蓝怡科技有限公司 | Serum or plasma sample diluent and application thereof |
| CN103602753A (en) * | 2013-12-09 | 2014-02-26 | 中国人民解放军第三军医大学第三附属医院 | Method and kit for detecting single nucleotide polymorphism site of LBP (Lipopolysaccharide-Binding Protein) genetic label |
Non-Patent Citations (1)
| Title |
|---|
| 徐霞: "血脂多糖结合蛋白、白介素-6 浓度与胎膜早破的相关性研究", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113008880A (en) * | 2021-02-26 | 2021-06-22 | 必为(上海)医疗器械有限公司 | Medical instrument residual blood detection kit and using method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Najjar et al. | A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma | |
| Cobo | Application of maldi-tof mass spectrometry in clinical virology: a review | |
| Belák § et al. | Molecular diagnosis of animal diseases: some experiences over the past decade | |
| Lévesque | Molecular methods for detection of plant pathogens—What is the future? | |
| Zhang et al. | SARS-CoV-2 detection using quantum dot fluorescence immunochromatography combined with isothermal amplification and CRISPR/Cas13a | |
| EP3508586A1 (en) | Method and kit for detecting pathogenic microorganism | |
| CN108291910A (en) | Running system and method for digital counting | |
| CN108411008A (en) | The application of 72 SNP sites and relevant primer in identifying or assisting identification human groups | |
| BR0206145A (en) | Indicator test system with reagent strip for use in liquids for the detection and/or determination of specific nucleic acid sequences | |
| Chen et al. | Target-protecting dumbbell molecular probe against exonucleases digestion for sensitive detection of ATP and streptavidin | |
| CN106191311B (en) | A kind of multiple liquid phase genetic chip method and reagent of quick detection cavy LCMV, SV, PVM, Reo-3 virus | |
| CN107328944B (en) | A kind of blood clotting and hemagglutination-inhibition test screening technique | |
| Rola et al. | The detection of bovine leukemia virus proviral DNA by PCR–ELISA | |
| CN109507323A (en) | A kind of kit with LBP content in mass spectrograph detection human blood | |
| US20220298589A1 (en) | Rna separation and related techniques for determining viruses such as coronaviruses | |
| CN105063760A (en) | Gene chip for identification of seven swine disease pathogens and detection method thereof | |
| CN101315379B (en) | Reagent kit for detecting Ractopamine and application thereof | |
| CN101629217A (en) | RT-LAMP detection kit and detection method of swine influenza virus | |
| CN103834747B (en) | The method of the detection H1N1virus pathogenicity based on pyrophosphoric acid order-checking | |
| CN106645108A (en) | Microporous plate chemiluminescence detection reagent and detection method | |
| CN106191319B (en) | A kind of multi-fluorescence immunoassay method of 6 kinds of fowl respiratory pathogens of quick differentiation | |
| CN109633176A (en) | A kind of nephrosis gene therapy diagnostic kit | |
| BR0210094A (en) | Method for measuring the expression ratio of a gene in the standard gene class | |
| US20200407769A1 (en) | Method for detecting enzymatic reaction product | |
| CN109868316A (en) | A method of detection 21 mutational sites of heredity high myopia gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190529 Address after: 518000 Huitong Building, No. 10 Longgang Road, Pingnan Community, Longgang Street, Longgang District, Shenzhen City, Guangdong Province, 805 Applicant after: Shenzhen Bogang Biotechnology Co., Ltd. Address before: Floor 1-2, Building No. 2, 500 Lane, Furong Hualu, Pudong New Area, Shanghai, 200120 Applicant before: Shanghai Haogang Biotechnology Co., Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190322 |